Background: Although COX-2 inhibitors are known to have adverse effects on myocardial ischemia, the effects of COX-2 inhibitors on cardiovascular diseases are still controversial. Thus, we hypothesized that COX-2 inhibitors affect pressure overloaded myocardial hypertrophy.
Methods and Results: To clarify the role, we used meloxicam in a murine transversal aortic banding (TAC) model. Meloxicam (0.5mg/kg) was given orally twice a day and the mice were sacrificed on day 28 (n=10) after TAC. The drugfree vehicle was used as control (n=7). Echocardiogram revealed that left ventricular (LV) wall thickness was significantly decreased in the meloxicam-treated group compared with the control group. Heart per body weight ratio of the meloxicam-treated group was substantially less than that of the non-treated group. Pathologically, hearts in the meloxicam- treated group showed significantly less LV wall thickness and area of myocardium than those in the control group. RT-PCR showed that COX-2 mRNA levels in hearts increased in the non-treated group, while meloxicam treatment suppressed the levels.
Conclusion: Meloxicam may be useful for preventing pressure overloaded myocardial hypertrophy.
Keywords: Echocardiogram, echocardiograms, histology, heart, blood pressure, COX-2 inhibitors, meloxicam, myocardial hypertrophy, mice, nonsteroidal anti-inflammatory drugs, pathology, pressure overload, transverse aortic constriction, pathology, polymerase chain reaction, wall thickness
The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury
Current Pharmaceutical Design Stress Echocardiography
Current Pharmaceutical Design TNNI3K Could be a Novel Molecular Target for the Treatment of Cardiac Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, its Potential Benefit in Angina and Other Cardiovascular Disorders
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Myocardial Ischemia-Reperfusion Injury, Antioxidant Enzyme Systems, and Selenium: A Review
Current Medicinal Chemistry The Mast Cell: A Potential Therapeutic Target in Myocardial Infarction
Drug Design Reviews - Online (Discontinued) Applied Pathology for Interventions of Coronary Chronic Total Occlusion
Current Cardiology Reviews Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Effect of SDF-1 α on Endogenous Mobilized and Transplanted Stem Cells in Regeneration after Myocardial Infarction
Current Pharmaceutical Design Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Inhibition of Mitochondrial Membrane Permeability as a Putative Pharmacological Target for Cardioprotection
Current Medicinal Chemistry Pleiotropic Effects of Cytokines on Acute Myocardial Infarction: G-CSF as A Novel Therapy for Acute Myocardial Infarction
Current Pharmaceutical Design Connexin43 and Myocardial Ischemia-Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Which are the Best Follow-Up Strategies for Patients Who Undergo Percutaneous Coronary Interventions?
Current Cardiology Reviews Detection of Myocardial Ischemia in Patients with Blunted Hemodynamic Response to Adenosine Stress
Current Medical Imaging